Efficacy of romiplostim in treatment of thrombocytopenia in children with Wiskott–Aldrich syndrome
Authors:
- Anna KhorevaAKAnna Khoreva
- Irina AbramovaIAIrina Abramova
- Elena DeripapaEDElena Deripapa
- Yulia RodinaYRYulia Rodina
- Anna RoppeltARAnna Roppelt
- Dmitry PershinDPDmitry Pershin
- Sergey LarinSLSergey Larin
- Kirill VoroninKVKirill Voronin
- Alexey MaschanAMAlexey Maschan
- Galina NovichkovaGNGalina Novichkova
- Anna ShcherbinaASAnna Shcherbina
Open Access
- 31 October 2020
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 192 (2) , 366-374
Abstract
Summary: Wiskott–Aldrich syndrome (WAS) is a life‐threatening primary immunodeficiency associated with bleeding of variable severity due to thrombocytopenia. Correction of the thrombocytopenia is of paramount importance for most WAS patients. We report a retrospective analysis of the safety and efficacy of romiplostim treatment in reducing thrombocytopenia and bleeding tendency in 67 children (median age 1·3 years) with genetically confirmed WAS, followed in eight months (range, 1–12 months). Complete or partial primary responses regarding platelet counts were observed in 22 (33%) and 18 (27%) subjects, respectively. Yet, even in the non‐responder group, the risk of haemorrhagic events decreased significantly, to 21%, after the first month of treatment. The responses tended to be durable and stable over time, with no significant fluctuations in platelets counts. The results of this retrospective study of a large cohort of WAS patients demonstrates that romiplostim can be used to increase platelet counts and reduce the risks of life‐threatening bleeding in WAS patients awaiting haematopoietic stem cell transplantation or forgoing the procedure for various reasons.Keywords
This publication has 48 references indexed in Scilit:
- High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human MegakaryocytesPLOS ONE, 2013
- Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative studyBlood, 2011
- Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 studyThe Lancet, 2011
- Romiplostim or Standard of Care in Patients with Immune ThrombocytopeniaNew England Journal of Medicine, 2010
- WASP plays a novel role in regulating platelet responses dependent on αIIbβ3 integrin outside‐in signallingBritish Journal of Haematology, 2010
- Thrombopoietin and Platelet Production in Chronic Immune ThrombocytopeniaHematology/Oncology Clinics of North America, 2009
- Rapid platelet turnover in WASP(−) mice correlates with increased ex vivo phagocytosis of opsonized WASP(−) plateletsExperimental Hematology, 2008
- Recombinant human thrombopoietin: basic biology and evaluation of clinical studiesBlood, 2002
- A multiinstitutional survey of the Wiskott-Aldrich syndromeThe Journal of Pediatrics, 1994
- Splenectomy in the Management of the Thrombocytopenia of the Wiskott–Aldrich SyndromeNew England Journal of Medicine, 1980